Dutch Investment Agency Bridges Critical Funding Gap for Healthcare Startups
Amsterdam, Friday, 20 March 2026.
ROM InWest strategically targets life sciences startups in North Holland’s thriving biotech cluster, addressing the notorious ‘Valley of Death’ that kills promising healthcare innovations. The regional agency fills a crucial funding void where traditional investors hesitate due to lengthy regulatory processes and slow healthcare adoption cycles. Recent investments include HeartEye’s one-minute wireless ECG technology and Amplio Pharma’s breakthrough drug that enhances arthritis treatment effectiveness while reducing costly biological therapies. With infection treatment alone costing hospitals €35 million annually, ROM InWest’s early-stage support enables AI-powered predictive care systems and other game-changing medical technologies to reach patients faster.
Targeting Three Critical Healthcare Innovation Areas
ROM InWest concentrates its investment strategy across three distinct domains within the Life Sciences & Health sector: digital health solutions, innovative medical equipment (MedTech), and biotechnology [1]. This focused approach addresses the most promising areas where North Holland startups can leverage the region’s scientific infrastructure. The Amsterdam Metropolitan Area hosts over 190 biotech companies and more than 20 leading institutes, supporting 10,000 jobs in research and development and technology [3]. Sara Schaafsma from ROM InWest emphasizes the agency’s crucial role, noting that “many LSH startups find it extremely difficult to find the right financing to grow” due to the unique challenges facing healthcare innovations [1].
Overcoming the Healthcare Innovation Valley of Death
The life sciences sector faces a particularly treacherous funding landscape known as the “Valley of Death,” where promising technologies fail to reach patients due to financial constraints [1]. MedTech companies encounter especially steep challenges requiring healthcare-specific CE certification, demanding extensive demonstrations of safety and efficacy before market entry [1]. ROM InWest addresses this critical gap by functioning as a bridge until traditional funding becomes available or commercial sales generate sufficient revenue [1]. The agency’s intervention strategy proves essential given the strict regulations and slow implementation cycles that characterize healthcare systems, making early-stage capital attraction exceptionally difficult for entrepreneurs in this sector [1].
Portfolio Companies Delivering Measurable Healthcare Impact
ROM InWest’s investment portfolio demonstrates tangible results across multiple healthcare challenges. The agency invested in HeartEye, which developed a wireless 12-channel ECG recorder that healthcare professionals can deploy in under one minute, dramatically reducing diagnostic time [1]. Amplio Pharma represents another success story with its NovoBioJect drug, which enhances the effectiveness of methotrexate for rheumatoid arthritis treatment while reducing side effects and delaying the need for expensive biological treatments [1]. Within three days of March 20, 2026, ROM InWest also invested in Healthplus.ai, which developed an AI system enabling hospitals to predict postoperative complications for individual patients, facilitating proactive care interventions [1].
Addressing Massive Healthcare Cost Burdens
The financial stakes underlying ROM InWest’s investment strategy become clear when examining current healthcare expenditures. Infection treatment alone costs the average hospital €35 million annually, representing a substantial burden that predictive AI systems could help reduce [1]. ROM InWest’s strategic positioning within North Holland’s life sciences cluster places it at the center of European healthcare innovation, with 25% of Dutch LSH activity concentrated in the Amsterdam region [3]. As Sara Schaafsma explains, “By functioning as a bridge to the moment when traditional funders can step in or there is sufficient revenue from commercial sales, we increase the chance that impactful innovations actually reach healthcare practice” [1]. This approach ensures that breakthrough medical technologies can navigate the challenging transition from research laboratories to patient care, ultimately strengthening the region’s position as a leading European hub for biotechnology and medical technology development.